Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1

Conditions

Rectal Neoplasms 2Pain 2Osteoporosis 2Neurotoxicity Syndromes 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Prostatic Neoplasms 1Paclitaxel-induced Neuropathy 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1Esophageal Neoplasms 1Arthralgia 1

Interventions

Cyclophosphamide 254fludarabine phosphate 165Cytarabine 160Methotrexate 128Busulfan 115Filgrastim 111fludarabine 102Peripheral Blood Stem Cell Transplantation 96Rituximab 94Antilymphocyte Serum 83Etoposide 81Cyclosporine 75Tacrolimus 74Mycophenolic Acid 73Whole-Body Irradiation 72Radiotherapy 70Melphalan 66Vincristine 55Dexamethasone 54Granulocyte Colony-Stimulating Factor 50Methylprednisolone 48Azacitidine 44Alemtuzumab 42Imatinib Mesylate 41Clofarabine 41sargramostim 40Idarubicin 36Daunorubicin 36Cord Blood Stem Cell Transplantation 36Mercaptopurine 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia × Calcium Gluconate × Clear all
NCT00321932 2017-03-09

Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

University of Minnesota

Phase 2 Completed
61 enrolled 16 charts
GynecologicLymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡